西格列汀全套雜質(zhì)

時(shí)間：2017/2/28閱讀：2115

西格列汀適應(yīng)癥及前景：磷酸西格列汀片是*個(gè)批準(zhǔn)用于治療2型糖尿病的DPP-4抑制劑，可抑制β細(xì)胞凋亡，促進(jìn)β細(xì)胞新生，增加2型糖尿病患者β細(xì)胞數(shù)量，明顯降低患者血糖，并且對(duì)磺脲類藥物失效的患者仍有顯著的降糖作用。磷酸西格列汀片主要通過配合運(yùn)動(dòng)和飲食控制實(shí)現(xiàn)對(duì)2型糖尿病患者的血糖控制。

經(jīng)上市后超過上千萬余張?zhí)幏降臋z驗(yàn)，西格列汀進(jìn)一步顯示出強(qiáng)有效的降糖療效和優(yōu)異的安全性，成為降糖藥物中耀眼的新星。西格列汀的巨大成功也獲得了醫(yī)藥科技界同仁的廣泛贊譽(yù)，各種獎(jiǎng)項(xiàng)接踵而至，其中zui值得一提的是2007年度的“愛迪生獎(jiǎng)”和“蓋倫獎(jiǎng)”等殊榮。2009 3月21日，中國國家食品藥品監(jiān)督管理局已正式批準(zhǔn)其捷諾維（磷酸西格列?。┰谥袊鲜?，使之成為國內(nèi)市場(chǎng)上*用于治療2型糖尿病的（DPP-4）抑制劑。

深圳遠(yuǎn)揚(yáng)化學(xué)技術(shù)有限公司提供西格列汀全套雜質(zhì)，隨貨提供結(jié)構(gòu)確認(rèn)圖譜，純度高，穩(wěn)定性好，（詳情請(qǐng)點(diǎn)擊本頁標(biāo)題下方“進(jìn)入該公司展臺(tái)” 查看我司信息）。

Sitagliptin	(R)-3-ami-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one
Sitagliptin Impurity 1	(R)-3-((tert-butoxycarbonyl)amino)-4-(3,4-difluorophenyl)butanoic acid
Sitagliptin Impurity 2	(R)-3-((tert-butoxycarbonyl)amino)-4-(2,4-difluorophenyl)butanoic acid
Sitagliptin Impurity 3	(R)-3-((tert-butoxycarbonyl)amino)-4-(2,5-difluorophenyl)butanoic acid
Sitagliptin Impurity 4	(S)-3-((tert-butoxycarbonyl)amino)-4-(2,4,5-trifluorophenyl)butanoic acid
Sitagliptin Impurity 5	(R)-methyl 3-((tert-butoxycarbonyl)amino)-4-(2,4,5-trifluorophenyl)butanoate
Sitagliptin Impurity 6	(R)-methyl 3-amino-4-(2,4,5-trifluorophenyl)butanoate
Sitagliptin Impurity 7	(R)-3-amino-4-(3,4-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-one
Sitagliptin Impurity 8	(R)-3-amino-4-(2,4-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-one
Sitagliptin Impurity 9	(R)-3-amino-4-(2,5-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-one
Sitagliptin Impurity 10	(R)-3-((tert-butoxycarbonyl)amino)-4-(2,4,5-trifluorophenyl)butanoic acid
Sitagliptin Impurity 11	(R)-tert-butyl (4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-yl)carbamate
Sitagliptin Impurity 12	(S)-3-ami-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one
Sitagliptin Impurity 13	1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butane-1,3-dione
Sitagliptin Impurity 14	(Z)-3-ami-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)but-2-en-1-one
Sitagliptin Impurity 15	(R)-3-amino-4-(2,4,5-trifluorophenyl)butanoic acid
Sitagliptin Impurity 16	(E)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)but-2-en-1-one
Sitagliptin Impurity 17	(E)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)but-3-en-1-one